Scientists at the U.S. Food and Drug Administration said on Tuesday that Moderna Inc had not met all of the agency's criteria to support use of booster doses of its COVID-19 vaccine, possibly because the efficacy of the shot's first two doses has remained strong.
Syringes filled with a dose of the Moderna COVID-19 vaccine sit on a table during an employee vaccination at the Sarasota Memorial Hospital in Sarasota, Florida, U.S., September 24, 2021. REUTERS/Shannon Stapletonhad not met all of the agency's criteria to support use of booster doses of its COVID-19 vaccine, possibly because the efficacy of the shot's first two doses has remained strong.
The FDA typically follows the advice of its experts, but is not bound to do so. A panel of advisers to the U.S. Centers for Disease Control and Prevention will meet next week to discuss specific recommendations on who can receive the boosters, if the FDA authorizes them. The company has asked regulators to clear a third round of shots for adults aged 65 and over, as well as for high-risk individuals, similar to the authorization gained by rivals Pfizer IncPresident Joe Biden's administration announced plans earlier this year to roll out booster doses for most adults, but some FDA scientists later said in an article in journal The Lancet that there was not enough evidence to support boosters for all.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Covid-19: NHS Covid passes, and lockdown lifted in SydneyFive things you need to know about the coronavirus pandemic this Monday morning.
Read more »
Moderna has no plans to share its COVID-19 vaccine recipeModerna's chairman, Noubar Afeyan, says the company won't share the recipe for its COVID-19 vaccine because scaling up its own production is the best way to increase the global supply. The U.N. health agency has pressed Moderna to share its formula.
Read more »
Where America's cases, hospitalizations, deaths stand 19 months into the COVID-19 pandemicAlthough hospitalizations nationwide have been trending downward since September, more than 40,000 people remain hospitalized with COVID-19.
Read more »
Merck seeks FDA emergency use authorization for antiviral Covid-19 treatment molnupiravirMerck said it is seeking FDA emergency use authorization for its experimental antiviral Covid-19 treatment, molnupiravir.
Read more »
Merck Seeks FDA Authorization for Antiviral COVID-19 PillDrugmaker Merck announced Monday that it submitted an application to the FDA for emergency use authorization of molnupiravir, an experimental antiviral COVID-19 treatment.
Read more »